uniQure (NASDAQ:QURE) Stock Price Down 7.3% Following Analyst Downgrade

uniQure (NASDAQ:QURE) shares dropped 7.3% during trading on Monday after Wells Fargo & Company lowered their price target on the stock from $35.00 to $30.00. Wells Fargo & Company currently has an equal weight rating on the stock. uniQure traded as low as $12.22 and last traded at $12.19. Approximately 151,018 shares changed hands during trading, a decline of 85% from the average daily volume of 1,001,427 shares. The stock had previously closed at $13.15.

A number of other brokerages have also commented on QURE. Leerink Partners upped their price objective on shares of uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a research report on Wednesday, December 11th. Guggenheim reissued a “buy” rating on shares of uniQure in a research report on Wednesday, December 11th. Mizuho upped their price objective on shares of uniQure from $7.00 to $20.00 and gave the stock a “neutral” rating in a research note on Thursday, December 19th. HC Wainwright upped their price objective on shares of uniQure from $25.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, January 27th. Finally, Stifel Nicolaus upped their price objective on shares of uniQure from $12.00 to $32.00 and gave the stock a “buy” rating in a research note on Monday, December 16th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, uniQure presently has a consensus rating of “Moderate Buy” and an average price target of $38.89.

Insider Buying and Selling at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 26,727 shares of the firm’s stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $10.70, for a total value of $285,978.90. Following the transaction, the chief executive officer now directly owns 571,188 shares of the company’s stock, valued at approximately $6,111,711.60. This trade represents a 4.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Christian Klemt sold 2,916 shares of the firm’s stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total transaction of $33,009.12. Following the completion of the transaction, the chief financial officer now directly owns 155,168 shares in the company, valued at approximately $1,756,501.76. The trade was a 1.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 55,915 shares of company stock valued at $588,112. 4.74% of the stock is currently owned by insiders.

Institutional Investors Weigh In On uniQure

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Avoro Capital Advisors LLC acquired a new stake in shares of uniQure during the fourth quarter worth $38,410,000. Franklin Resources Inc. raised its holdings in shares of uniQure by 33.1% during the fourth quarter. Franklin Resources Inc. now owns 1,987,688 shares of the biotechnology company’s stock worth $35,103,000 after acquiring an additional 494,726 shares during the period. Point72 Asset Management L.P. raised its holdings in shares of uniQure by 81.3% during the fourth quarter. Point72 Asset Management L.P. now owns 1,771,352 shares of the biotechnology company’s stock worth $31,282,000 after acquiring an additional 794,459 shares during the period. Integral Health Asset Management LLC grew its position in uniQure by 175.0% in the fourth quarter. Integral Health Asset Management LLC now owns 1,100,000 shares of the biotechnology company’s stock valued at $19,426,000 after purchasing an additional 700,000 shares in the last quarter. Finally, RTW Investments LP grew its position in uniQure by 8,936.3% in the fourth quarter. RTW Investments LP now owns 903,625 shares of the biotechnology company’s stock valued at $15,958,000 after purchasing an additional 893,625 shares in the last quarter. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure Trading Down 17.1 %

The firm has a market cap of $531.30 million, a P/E ratio of -2.20 and a beta of 0.38. The business’s 50-day moving average is $14.92 and its two-hundred day moving average is $9.86. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.